Tissue factor pathway inhibitor alpha (TFPI-alpha) (TFPI-alpha)

Tissue factor pathway inhibitor alpha (TFPI-alpha) is a multivalent Kunitz-type serine protease inhibitor that serves as the principal regulator of the initiation of the extrinsic coagulation pathway (Broze & Girard, 2012; NIH, 2024). The TFPI-alpha isoform is the predominant full-length version in humans, characterized by three tandem Kunitz-type domains (K1, K2, and K3) and a basic C-terminal tail (UniProt; NIH, 2018). The Kunitz-2 (K2) domain is functionally critical as it directly binds and neutralizes activated Factor X (FXa), which is a rate-limiting step in the inhibition of the coagulation cascade (NIH, 2021; ResearchGate). In the context of hemophilia A and B, the deficiency of intrinsic clotting factors (FVIII or FIX) makes the extrinsic pathway the primary source of thrombin, but its activity is naturally constrained by TFPI-alpha (Pfizer, 2023; JAPI, 2025). By targeting the K2 domain of TFPI-alpha, therapeutic monoclonal antibodies like concizumab and marstacimab prevent the inhibition of FXa, thereby "rebalancing" the hemostatic system to favor clot formation (NIH, 2021; PatSnap, 2025). This "inhibit the inhibitor" strategy allows for sustained thrombin generation and provides a prophylactic treatment option that is effective regardless of whether a patient has developed inhibitors to replacement factors (Novo Nordisk; Pfizer, 2025). Clinical applications of these agents focus on reducing the frequency of bleeding episodes in patients with severe hemophilia (Bleeding.org, 2025). Beyond its role in hemostasis, TFPI-alpha is also involved in inflammatory processes and vascular biology through its interactions with various cell surface receptors and the extracellular matrix (NIH, 2024).

Other names

TFPI1Tissue factor pathway inhibitor 1Lipoprotein-associated coagulation inhibitorLACIExtrinsic pathway inhibitorEPITissue factor inhibitorTFI

Inhibition of the Kunitz-2 domain of TFPI-alpha to prevent its binding to and neutralization of activated Factor X (FXa), thereby enhancing thrombin generation and restoring hemostatic balance (NIH, 2021; Pfizer, 2025).